Healthcare Pharmaceutical Biotech

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026 8:30 AM

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo (DRC), with spillage across the border into Uganda. "We believe NV-387 could be effective against the Bundibugyo strain of Ebola that is...

Read more

Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology

May 18, 2026 8:10 AM

XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of a regulatory derogation for XVIVO's heart technology back in December 2025, performed 11 heart transplants that would otherwise not have taken place, saving precious lives. In addition, XVIVO's heart technology has now also received reimbursement in France. A regulatory derogation allows a medical...

Read more

June 29 Marijuana Rescheduling Hearing Faces Constitutional Issues Before It Even Begins

May 18, 2026 6:00 AM

The federal government's highly publicized plan to move marijuana from Schedule I to Schedule III faces a structural legal problem that political momentum cannot erase: the Department of Justice has formally admitted in federal court that the DEA Administrative Law Judge ("ALJ") structure violates the United States Constitution, while the same administrative system is still expected to conduct marijuana rescheduling hearings. This...

Read more

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

May 18, 2026 2:40 AM

Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor...

Read more

CK Life Sciences' Sequencio Therapeutics Appoints Emily Tan as Chief Operating Officer

May 18, 2026 1:42 AM

Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences", Stock Code:0775) today announced the appointment of Emily Tan as Chief Operating Officer. A 30-year biopharmaceutical veteran, Ms Tan will oversee the company's global operations and drive execution across its development pipeline. Ms Tan joins Sequencio Therapeutics with an extensive track record across global pharmaceutical companies, leading...

Read more

MedSyntra Advances Sovereign Healthcare AI Vision and Appoints Dr George Syrmalis to Board of Directors

May 17, 2026 2:00 AM

MedSyntra, a company operating at the intersection of healthcare, artificial intelligence, and sovereign medical data infrastructure, today announced the continued expansion of its strategic and governance capabilities - including the appointment of Dr George Syrmalis to its Board of Directors - as it advances the development of institutionally governed healthcare AI ecosystems. The company is focused on building scalable healthcare...

Read more

State Cannabis Companies Rushed To Apply for DEA Registration but DEA Cannot Rewrite Marijuana Federal Register Rules With a Press Statement

May 16, 2026 11:30 AM

The moment the federal government opened the door to new Schedule III marijuana registration pathways, state cannabis companies rushed toward it. Major operators began filing DEA registration applications almost immediately, hoping for: federal legitimacy, easier banking, and relief from crushing IRS 280E taxes. But there is one major problem: The DEA's own binding Final Rule published in 2020 says many of those companies spent years operating...

Read more

Europe's Hospital Cyber Risk Has Moved From Data Theft to Care Disruption, Black Book Study Warns Ahead of HIMSS26 Europe

May 16, 2026 10:00 AM

Black Book Research today released findings from its Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey, warning that hospital cyber risk across Europe has entered a more dangerous phase: attacks are no longer viewed primarily as privacy events, compliance events, or IT disruptions. They are now being evaluated as direct threats to care delivery. The survey of 284 self-identified HIMSS26 attendees from European hospital, health...

Read more

ClinicsSpots Named Medical Prep One of the Top Online Medical Assistant Training Programs of 2026

May 16, 2026 7:30 AM

In its 2026 review of medical assistant programs, ClinicsSpots ranked Medical Prep among the leading options for students pursuing medical assistant training. The recognition reflects Medical Prep's emphasis on accessible career guidance, certification preparation, flexible learning considerations, and practical program-selection support. For prospective students comparing medical assistant pathways, the updated MedicalPrep training resource...

Read more

Keeps TRT Reviews 2026: What Men Should Know About Online Testosterone Replacement Therapy, Pricing, Labs, and Safety

May 15, 2026 6:40 PM

Advertorial Disclosure: This article is sponsored advertorial content. This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products or services. Disclosure is provided in accordance with FTC 16 CFR Part 255. The statements in this article have not been...

Read more

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

May 15, 2026 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advanced its Chemistry, Manufacturing and Controls ("CMC") development program through the initiation of analytical method validation activities for assay, related substances, and residual solvents for A83B4C63, the active pharmaceutical ingredient ("API") for Onco's exclusively-licensed PNKP Inhibitor...

Read more

Ensysce Biosciences Reports First Quarter 2026 Financial Results

May 15, 2026 4:15 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today reported financial and operational results for the first quarter ended March 31, 2026. "The first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, underscoring the...

Read more

Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026

May 15, 2026 4:01 PM

Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026. About Wellgistics Health, Inc. Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence...

Read more

Taurus Charge Reviewed: The 4-in-1 Sublingual Prescription ED Program From Taurus Medical - Pricing, Process, and What to Verify Before Starting

May 15, 2026 3:30 PM

Disclosure: This article contains sponsored content and affiliate links. If a purchase is made through links in this article, a commission may be earned at no additional cost to the reader. This content is for informational purposes only and is not medical advice. Taurus Charge is a prescription compounded ED medication available only after review by a licensed healthcare provider. Prescription approval is not guaranteed. Individual results...

Read more

Glidewell TV Celebrates One Year of On-Demand Dental Education

May 15, 2026 11:00 AM

Glidewell, America's foremost dental laboratory and longtime provider of world-class continuing education solutions, is celebrating the one-year anniversary of Glidewell TV, reflecting on the significant growth and looking ahead to an expanded slate of original programming as the free streaming service enters its second year. Positioned as the "Netflix of dentistry," Glidewell TV was launched to give dental professionals access to practical,...

Read more

John H. Weston Jr. Releases Free "Early Warning Signs" Checklist to Help Prevent Behavioral Crises

May 15, 2026 10:50 AM

John H. Weston Jr. today announced the release of a free behavioral support resource titled the "15-Minute Early Warning Signs Checklist." The tool is designed for families, caregivers, support staff, educators, and everyday individuals who want a simple way to identify stress patterns before they turn into behavioral crises. The checklist focuses on practical observation, predictable routines, and early intervention. It was built around the...

Read more

CVS Health’s Annual Impact in Rhode Island

May 15, 2026 9:00 AM

With more than 9,000 locations and 300,000 employees, CVS Health is a driving force in the American economy, delivering $474 billion in economic impact nationwide. As one of the country's largest private employers, we're making health care more affordable and accessible for you and your family. Discover how our economic footprint benefits communities across the U.S: creating jobs, fueling local investments and generating tax revenue that...

Read more

EHDS Readiness Shifts from EU Policy to Provider Budget and Vendor Accountability

May 15, 2026 8:55 AM

Black Book Research today released pre-HIMSS26 Europe findings from a 14-country study of 881 healthcare technology, finance, clinical informatics, procurement, and data governance leaders, concluding that European Health Data Space readiness is no longer primarily a Brussels policy debate. It is now a provider execution test involving funding, vendor commitments, EHR readiness, data quality, and secondary-use operations. The study, conducted...

Read more

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

May 15, 2026 8:35 AM

NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares (or...

Read more

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

May 15, 2026 8:00 AM

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2026 with the Securities and Exchange Commission (SEC) on Thursday, May 14, 2026. The report can be accessed at the SEC website by searching for the Company (https://www.sec.gov/edgar/browse/?CIK=1379006&owner=exclude) . Clinical Stage NV-387, a Single Drug, Meets Many Unmet Medical Needs in...

Read more